ARISE Study No Longer Enrolling

The Janssen Research and Development, LLC ARISE Study for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) is no longer accepting new participants and will move forward with analysis of the study data. This decision was made after thoughtful review of our goals and future plans and considering operational challenges in the study’s
execution.

There was no new information about the investigational compound, nor were there any safety signals that affected this decision. This is a unique, study-specific determination.

Although enrollment has been limited to patients who will have been screened by 11 September 2026, all participants who have already begun taking part in the study will continue per the protocol, including the option to enroll in the long-term extension, if qualified based on the pre-established
study qualifications. We believe this decision will help us continue to discover important information about the potential of investigational medications in the treatment of CIDP. And, we remain committed to you, our patient community, through our Johnson & Johnson Credo, which is at the heart of everything we do!

Johnson & Johnson remains deeply committed to advancing new investigational medications for rare diseases like CIDP in the future.

Sincerely,
Janssen Research & Development, LLC ARISE Team

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.